๐Ÿ’พ Data Updated: 2025 HTS Revision 30 โ€ข Last updated: November 24, 2025

2933.39.41.00 - Other

Details

FieldValue
Unit of Quantitykg
General Rate of Duty6.5%
Special Rate of DutyFree (A+,AU,BH,CL,CO,D,E,IL,JO,K,KR,MA,OM,P,PA,PE,S,SG)
A+ ๐Ÿ‡ฆ๐Ÿ‡ซ ๐Ÿ‡ฆ๐Ÿ‡ด ๐Ÿ‡ง๐Ÿ‡ฏ ๐Ÿ‡ง๐Ÿ‡น ๐Ÿ‡ง๐Ÿ‡ซ ๐Ÿ‡ง๐Ÿ‡ฎ ๐Ÿ‡ฐ๐Ÿ‡ญ ๐Ÿ‡จ๐Ÿ‡ซ ๐Ÿ‡น๐Ÿ‡ฉ ๐Ÿ‡ฐ๐Ÿ‡ฒ ๐Ÿ‡จ๐Ÿ‡ฉ ๐Ÿ‡ฉ๐Ÿ‡ฏ ๐Ÿ‡ช๐Ÿ‡น ๐Ÿ‡ฌ๐Ÿ‡ฒ ๐Ÿ‡ฌ๐Ÿ‡ณ ๐Ÿ‡ฌ๐Ÿ‡ผ ๐Ÿ‡ญ๐Ÿ‡น ๐Ÿ‡ฐ๐Ÿ‡ฎ ๐Ÿ‡ฑ๐Ÿ‡ธ ๐Ÿ‡ฑ๐Ÿ‡ท ๐Ÿ‡ฒ๐Ÿ‡ฌ ๐Ÿ‡ฒ๐Ÿ‡ผ ๐Ÿ‡ฒ๐Ÿ‡ฑ ๐Ÿ‡ฒ๐Ÿ‡ท ๐Ÿ‡ฒ๐Ÿ‡ฟ ๐Ÿ‡ฒ๐Ÿ‡ฒ ๐Ÿ‡ณ๐Ÿ‡ต ๐Ÿ‡ณ๐Ÿ‡ช ๐Ÿ‡ท๐Ÿ‡ผ ๐Ÿ‡ผ๐Ÿ‡ธ ๐Ÿ‡ธ๐Ÿ‡ณ ๐Ÿ‡ธ๐Ÿ‡ฑ ๐Ÿ‡ธ๐Ÿ‡ง ๐Ÿ‡ธ๐Ÿ‡ด ๐Ÿ‡ธ๐Ÿ‡ธ ๐Ÿ‡ธ๐Ÿ‡น ๐Ÿ‡น๐Ÿ‡ฟ ๐Ÿ‡น๐Ÿ‡ฑ ๐Ÿ‡น๐Ÿ‡ฌ ๐Ÿ‡น๐Ÿ‡ป ๐Ÿ‡บ๐Ÿ‡ฌ ๐Ÿ‡ป๐Ÿ‡บ ๐Ÿ‡พ๐Ÿ‡ช ๐Ÿ‡ฟ๐Ÿ‡ฒ
AU ๐Ÿ‡ฆ๐Ÿ‡บ
BH ๐Ÿ‡ง๐Ÿ‡ญ
CL ๐Ÿ‡จ๐Ÿ‡ฑ
CO ๐Ÿ‡จ๐Ÿ‡ด
D ๐Ÿ‡ฆ๐Ÿ‡ด ๐Ÿ‡ง๐Ÿ‡ฏ ๐Ÿ‡ง๐Ÿ‡ผ ๐Ÿ‡ง๐Ÿ‡ซ ๐Ÿ‡จ๐Ÿ‡ป ๐Ÿ‡จ๐Ÿ‡ซ ๐Ÿ‡น๐Ÿ‡ฉ ๐Ÿ‡ฐ๐Ÿ‡ฒ ๐Ÿ‡จ๐Ÿ‡ฎ ๐Ÿ‡จ๐Ÿ‡ฉ ๐Ÿ‡ฉ๐Ÿ‡ฏ ๐Ÿ‡ธ๐Ÿ‡ฟ ๐Ÿ‡ช๐Ÿ‡น ๐Ÿ‡ฌ๐Ÿ‡ฆ ๐Ÿ‡ฌ๐Ÿ‡ฒ ๐Ÿ‡ฌ๐Ÿ‡ญ ๐Ÿ‡ฌ๐Ÿ‡ณ ๐Ÿ‡ฌ๐Ÿ‡ผ ๐Ÿ‡ฐ๐Ÿ‡ช ๐Ÿ‡ฑ๐Ÿ‡ธ ๐Ÿ‡ฑ๐Ÿ‡ท ๐Ÿ‡ฒ๐Ÿ‡ฌ ๐Ÿ‡ฒ๐Ÿ‡ผ ๐Ÿ‡ฒ๐Ÿ‡ฑ ๐Ÿ‡ฒ๐Ÿ‡บ ๐Ÿ‡ฒ๐Ÿ‡ฟ ๐Ÿ‡ณ๐Ÿ‡ฆ ๐Ÿ‡ณ๐Ÿ‡ช ๐Ÿ‡ณ๐Ÿ‡ฌ ๐Ÿ‡จ๐Ÿ‡ฌ ๐Ÿ‡ท๐Ÿ‡ผ ๐Ÿ‡ธ๐Ÿ‡ณ ๐Ÿ‡ธ๐Ÿ‡ฑ ๐Ÿ‡ฟ๐Ÿ‡ฆ ๐Ÿ‡ธ๐Ÿ‡น ๐Ÿ‡น๐Ÿ‡ฟ ๐Ÿ‡น๐Ÿ‡ฌ ๐Ÿ‡บ๐Ÿ‡ฌ ๐Ÿ‡ฟ๐Ÿ‡ฒ
E ๐Ÿ‡ฆ๐Ÿ‡ฌ ๐Ÿ‡ฆ๐Ÿ‡ผ ๐Ÿ‡ง๐Ÿ‡ธ ๐Ÿ‡ง๐Ÿ‡ง ๐Ÿ‡ง๐Ÿ‡ฟ ๐Ÿ‡ป๐Ÿ‡ฌ ๐Ÿ‡จ๐Ÿ‡ผ ๐Ÿ‡ฉ๐Ÿ‡ฒ ๐Ÿ‡ฌ๐Ÿ‡ฉ ๐Ÿ‡ฌ๐Ÿ‡พ ๐Ÿ‡ญ๐Ÿ‡น ๐Ÿ‡ฏ๐Ÿ‡ฒ ๐Ÿ‡ฒ๐Ÿ‡ธ NE ๐Ÿ‡ฐ๐Ÿ‡ณ ๐Ÿ‡ฑ๐Ÿ‡จ ๐Ÿ‡ป๐Ÿ‡จ ๐Ÿ‡น๐Ÿ‡น
IL ๐Ÿ‡ฎ๐Ÿ‡ฑ
JO ๐Ÿ‡ฏ๐Ÿ‡ด
K ๐Ÿ‡ฆ๐Ÿ‡ซ ๐Ÿ‡ฆ๐Ÿ‡ฑ ๐Ÿ‡ฆ๐Ÿ‡ฉ ๐Ÿ‡ฆ๐Ÿ‡ด ๐Ÿ‡ฆ๐Ÿ‡ฎ ๐Ÿ‡ฆ๐Ÿ‡ฌ ๐Ÿ‡ฆ๐Ÿ‡ท ๐Ÿ‡ฆ๐Ÿ‡ฒ ๐Ÿ‡ฆ๐Ÿ‡ผ ๐Ÿ‡ฆ๐Ÿ‡บ ๐Ÿ‡ฆ๐Ÿ‡น ๐Ÿ‡ฆ๐Ÿ‡ฟ ๐Ÿ‡ง๐Ÿ‡ธ ๐Ÿ‡ง๐Ÿ‡ญ ๐Ÿ‡ง๐Ÿ‡ฉ ๐Ÿ‡ง๐Ÿ‡ง ๐Ÿ‡ง๐Ÿ‡พ ๐Ÿ‡ง๐Ÿ‡ช ๐Ÿ‡ง๐Ÿ‡ฟ ๐Ÿ‡ง๐Ÿ‡ฏ ๐Ÿ‡ง๐Ÿ‡ฒ ๐Ÿ‡ง๐Ÿ‡น ๐Ÿ‡ง๐Ÿ‡ด ๐Ÿ‡ง๐Ÿ‡ฆ ๐Ÿ‡ง๐Ÿ‡ผ ๐Ÿ‡ง๐Ÿ‡ท ๐Ÿ‡ฎ๐Ÿ‡ด ๐Ÿ‡ป๐Ÿ‡ฌ ๐Ÿ‡ง๐Ÿ‡ณ ๐Ÿ‡ง๐Ÿ‡ฌ ๐Ÿ‡ง๐Ÿ‡ซ ๐Ÿ‡ง๐Ÿ‡ฎ ๐Ÿ‡จ๐Ÿ‡ป ๐Ÿ‡ฐ๐Ÿ‡ญ ๐Ÿ‡จ๐Ÿ‡ฒ ๐Ÿ‡จ๐Ÿ‡ฆ ๐Ÿ‡ฐ๐Ÿ‡พ ๐Ÿ‡จ๐Ÿ‡ซ ๐Ÿ‡น๐Ÿ‡ฉ ๐Ÿ‡จ๐Ÿ‡ฑ ๐Ÿ‡จ๐Ÿ‡ณ ๐Ÿ‡จ๐Ÿ‡ฝ ๐Ÿ‡จ๐Ÿ‡จ ๐Ÿ‡จ๐Ÿ‡ด ๐Ÿ‡ฐ๐Ÿ‡ฒ ๐Ÿ‡จ๐Ÿ‡ฐ ๐Ÿ‡จ๐Ÿ‡ท ๐Ÿ‡ญ๐Ÿ‡ท ๐Ÿ‡จ๐Ÿ‡พ ๐Ÿ‡จ๐Ÿ‡ฟ ๐Ÿ‡จ๐Ÿ‡ฟ ๐Ÿ‡จ๐Ÿ‡ฎ ๐Ÿ‡จ๐Ÿ‡ฉ ๐Ÿ‡ฉ๐Ÿ‡ฐ ๐Ÿ‡ฉ๐Ÿ‡ฏ ๐Ÿ‡ฉ๐Ÿ‡ฒ ๐Ÿ‡ฉ๐Ÿ‡ด EA ๐Ÿ‡ช๐Ÿ‡จ ๐Ÿ‡ช๐Ÿ‡ฌ ๐Ÿ‡ธ๐Ÿ‡ป ๐Ÿ‡ฌ๐Ÿ‡ถ ๐Ÿ‡ช๐Ÿ‡ท ๐Ÿ‡ช๐Ÿ‡ช ๐Ÿ‡ธ๐Ÿ‡ฟ ๐Ÿ‡ช๐Ÿ‡น ET ๐Ÿ‡ซ๐Ÿ‡ฐ ๐Ÿ‡ซ๐Ÿ‡ด ๐Ÿ‡ซ๐Ÿ‡ฏ ๐Ÿ‡ซ๐Ÿ‡ฎ ๐Ÿ‡ซ๐Ÿ‡ท ๐Ÿ‡ฌ๐Ÿ‡ซ ๐Ÿ‡ต๐Ÿ‡ซ ๐Ÿ‡น๐Ÿ‡ซ ๐Ÿ‡ฌ๐Ÿ‡ฆ ๐Ÿ‡ฌ๐Ÿ‡ฒ ๐Ÿ‡ต๐Ÿ‡ธ ๐Ÿ‡ฌ๐Ÿ‡ช ๐Ÿ‡ฉ๐Ÿ‡ช ๐Ÿ‡ฌ๐Ÿ‡ญ ๐Ÿ‡ฌ๐Ÿ‡ฎ ๐Ÿ‡ฌ๐Ÿ‡ท ๐Ÿ‡ฌ๐Ÿ‡ฑ ๐Ÿ‡ฌ๐Ÿ‡ฉ ๐Ÿ‡ฌ๐Ÿ‡ต ๐Ÿ‡ฌ๐Ÿ‡น ๐Ÿ‡ฌ๐Ÿ‡ณ ๐Ÿ‡ฌ๐Ÿ‡ผ ๐Ÿ‡ฌ๐Ÿ‡พ ๐Ÿ‡ญ๐Ÿ‡น ๐Ÿ‡ญ๐Ÿ‡ฒ ๐Ÿ‡ญ๐Ÿ‡ณ ๐Ÿ‡ญ๐Ÿ‡ฐ ๐Ÿ‡ญ๐Ÿ‡บ ๐Ÿ‡ฎ๐Ÿ‡ธ ๐Ÿ‡ฎ๐Ÿ‡ณ ๐Ÿ‡ฎ๐Ÿ‡ฉ IN ๐Ÿ‡ฎ๐Ÿ‡ท ๐Ÿ‡ฎ๐Ÿ‡ถ ๐Ÿ‡ฎ๐Ÿ‡ช ๐Ÿ‡ฎ๐Ÿ‡ฑ IS ๐Ÿ‡ฎ๐Ÿ‡น ๐Ÿ‡ฏ๐Ÿ‡ฒ ๐Ÿ‡ฏ๐Ÿ‡ต ๐Ÿ‡ฏ๐Ÿ‡ด ๐Ÿ‡ฐ๐Ÿ‡ฟ ๐Ÿ‡ฐ๐Ÿ‡ช ๐Ÿ‡ฐ๐Ÿ‡ฎ KO ๐Ÿ‡ฐ๐Ÿ‡ผ ๐Ÿ‡ฐ๐Ÿ‡ฌ ๐Ÿ‡ฑ๐Ÿ‡ฆ ๐Ÿ‡ฑ๐Ÿ‡ป ๐Ÿ‡ฑ๐Ÿ‡ง ๐Ÿ‡ฑ๐Ÿ‡ธ ๐Ÿ‡ฑ๐Ÿ‡ท ๐Ÿ‡ฑ๐Ÿ‡พ ๐Ÿ‡ฑ๐Ÿ‡ฎ ๐Ÿ‡ฑ๐Ÿ‡น ๐Ÿ‡ฑ๐Ÿ‡บ ๐Ÿ‡ฒ๐Ÿ‡ด ๐Ÿ‡ฒ๐Ÿ‡ฌ ๐Ÿ‡ฒ๐Ÿ‡ผ ๐Ÿ‡ฒ๐Ÿ‡พ ๐Ÿ‡ฒ๐Ÿ‡ป ๐Ÿ‡ฒ๐Ÿ‡ฑ ๐Ÿ‡ฒ๐Ÿ‡น ๐Ÿ‡ฒ๐Ÿ‡ญ ๐Ÿ‡ฒ๐Ÿ‡ถ ๐Ÿ‡ฒ๐Ÿ‡ท ๐Ÿ‡ฒ๐Ÿ‡บ ๐Ÿ‡พ๐Ÿ‡น ๐Ÿ‡ฒ๐Ÿ‡ฝ ๐Ÿ‡ซ๐Ÿ‡ฒ ๐Ÿ‡ฒ๐Ÿ‡ฉ ๐Ÿ‡ฒ๐Ÿ‡จ ๐Ÿ‡ฒ๐Ÿ‡ณ ๐Ÿ‡ฒ๐Ÿ‡ช ๐Ÿ‡ฒ๐Ÿ‡ธ ๐Ÿ‡ฒ๐Ÿ‡ฆ ๐Ÿ‡ฒ๐Ÿ‡ฟ ๐Ÿ‡ฒ๐Ÿ‡ฒ ๐Ÿ‡ณ๐Ÿ‡ฆ ๐Ÿ‡ณ๐Ÿ‡ท ๐Ÿ‡ณ๐Ÿ‡ต ๐Ÿ‡ณ๐Ÿ‡ฑ NE ๐Ÿ‡ณ๐Ÿ‡จ ๐Ÿ‡ณ๐Ÿ‡ฟ ๐Ÿ‡ณ๐Ÿ‡ฎ ๐Ÿ‡ณ๐Ÿ‡ช ๐Ÿ‡ณ๐Ÿ‡ฌ ๐Ÿ‡ณ๐Ÿ‡บ ๐Ÿ‡ณ๐Ÿ‡ซ ๐Ÿ‡ฒ๐Ÿ‡ฐ ๐Ÿ‡ณ๐Ÿ‡ด ๐Ÿ‡ด๐Ÿ‡ฒ ๐Ÿ‡ต๐Ÿ‡ฐ ๐Ÿ‡ต๐Ÿ‡ผ ๐Ÿ‡ต๐Ÿ‡ฆ ๐Ÿ‡ต๐Ÿ‡ฌ ๐Ÿ‡ต๐Ÿ‡พ ๐Ÿ‡ต๐Ÿ‡ช ๐Ÿ‡ต๐Ÿ‡ญ ๐Ÿ‡ต๐Ÿ‡ณ ๐Ÿ‡ต๐Ÿ‡ฑ ๐Ÿ‡ต๐Ÿ‡น ๐Ÿ‡ต๐Ÿ‡ท ๐Ÿ‡ถ๐Ÿ‡ฆ ๐Ÿ‡จ๐Ÿ‡ฌ ๐Ÿ‡ท๐Ÿ‡ช ๐Ÿ‡ท๐Ÿ‡ด ๐Ÿ‡ท๐Ÿ‡บ ๐Ÿ‡ท๐Ÿ‡ผ ๐Ÿ‡ธ๐Ÿ‡ญ ๐Ÿ‡ฐ๐Ÿ‡ณ ๐Ÿ‡ฑ๐Ÿ‡จ ๐Ÿ‡ต๐Ÿ‡ฒ ๐Ÿ‡ป๐Ÿ‡จ ๐Ÿ‡ผ๐Ÿ‡ธ ๐Ÿ‡ธ๐Ÿ‡ฒ ๐Ÿ‡ธ๐Ÿ‡ฆ SA ๐Ÿ‡ธ๐Ÿ‡ณ ๐Ÿ‡ท๐Ÿ‡ธ SE SE ๐Ÿ‡ธ๐Ÿ‡จ ๐Ÿ‡ธ๐Ÿ‡ฑ ๐Ÿ‡ธ๐Ÿ‡ฌ ๐Ÿ‡ธ๐Ÿ‡ฐ ๐Ÿ‡ธ๐Ÿ‡ฎ ๐Ÿ‡ธ๐Ÿ‡ง ๐Ÿ‡ธ๐Ÿ‡ด ๐Ÿ‡ฟ๐Ÿ‡ฆ ๐Ÿ‡ฐ๐Ÿ‡ท ๐Ÿ‡ธ๐Ÿ‡ธ SO SO ๐Ÿ‡ช๐Ÿ‡ธ ๐Ÿ‡ฑ๐Ÿ‡ฐ ๐Ÿ‡ธ๐Ÿ‡ฉ SU ๐Ÿ‡ธ๐Ÿ‡ท ๐Ÿ‡ธ๐Ÿ‡ฏ ๐Ÿ‡ธ๐Ÿ‡ช ๐Ÿ‡จ๐Ÿ‡ญ ๐Ÿ‡ธ๐Ÿ‡พ ๐Ÿ‡ธ๐Ÿ‡น ๐Ÿ‡น๐Ÿ‡ผ ๐Ÿ‡น๐Ÿ‡ฏ ๐Ÿ‡น๐Ÿ‡ฟ ๐Ÿ‡น๐Ÿ‡ญ ๐Ÿ‡น๐Ÿ‡ฑ ๐Ÿ‡น๐Ÿ‡ฌ ๐Ÿ‡น๐Ÿ‡ฐ ๐Ÿ‡น๐Ÿ‡ด TR ๐Ÿ‡น๐Ÿ‡น ๐Ÿ‡น๐Ÿ‡ณ ๐Ÿ‡น๐Ÿ‡ท ๐Ÿ‡น๐Ÿ‡ฒ ๐Ÿ‡น๐Ÿ‡จ ๐Ÿ‡น๐Ÿ‡ป ๐Ÿ‡บ๐Ÿ‡ฌ ๐Ÿ‡บ๐Ÿ‡ฆ ๐Ÿ‡ฆ๐Ÿ‡ช ๐Ÿ‡ฌ๐Ÿ‡ง UN ๐Ÿ‡บ๐Ÿ‡พ ๐Ÿ‡บ๐Ÿ‡ฟ ๐Ÿ‡ป๐Ÿ‡บ ๐Ÿ‡ป๐Ÿ‡ฆ ๐Ÿ‡ป๐Ÿ‡ช ๐Ÿ‡ป๐Ÿ‡ณ ๐Ÿ‡ผ๐Ÿ‡ซ ๐Ÿ‡ต๐Ÿ‡ธ ๐Ÿ‡ช๐Ÿ‡ญ ๐Ÿ‡พ๐Ÿ‡ช ๐Ÿ‡ฟ๐Ÿ‡ฒ ๐Ÿ‡ฟ๐Ÿ‡ผ
KR ๐Ÿ‡ฐ๐Ÿ‡ท
MA ๐Ÿ‡ฒ๐Ÿ‡ฆ
OM ๐Ÿ‡ด๐Ÿ‡ฒ
P ๐Ÿ‡จ๐Ÿ‡ท ๐Ÿ‡ฉ๐Ÿ‡ด ๐Ÿ‡ธ๐Ÿ‡ป ๐Ÿ‡ฌ๐Ÿ‡น ๐Ÿ‡ญ๐Ÿ‡ณ ๐Ÿ‡ณ๐Ÿ‡ฎ
PA ๐Ÿ‡ต๐Ÿ‡ฆ
PE ๐Ÿ‡ต๐Ÿ‡ช
S ๐Ÿ‡จ๐Ÿ‡ฆ ๐Ÿ‡ฒ๐Ÿ‡ฝ
SG ๐Ÿ‡ธ๐Ÿ‡ฌ
Column 2 Rate of Duty15.4ยข/kg + 65%
Quota QuantityN/A
Additional DutiesN/A

Overview

This HTS category, 2933.39.41.00, encompasses "Other" drugs that contain an unfused pyridine ring as a structural component. This classification is specifically for pharmaceutical substances intended for therapeutic or prophylactic use that do not fall into the more narrowly defined subcategories within the broader "Drugs" heading. The key characteristic is the presence of a pyridine ring, a six-membered heterocyclic aromatic organic compound containing one nitrogen atom, which is not fused to other ring systems.

It is crucial to distinguish this category from its sibling, 2933.39.31.00, which is designated for antidepressants, tranquilizers, and other psychotherapeutic agents. While both categories deal with pyridine-containing drugs, 2933.39.41.00 serves as a residual category for all other drug classes that meet the pyridine ring structural requirement but are not primarily psychotherapeutic. Therefore, if a pyridine-containing compound is a pharmaceutical drug but its primary function is not related to the central nervous system as defined by psychotherapeutic agents, it would likely be classified here.

As this is a leaf node, there are no further subdivisions under 2933.39.41.00. Classification at this level requires a thorough understanding of the chemical structure of the drug, specifically the presence of the unfused pyridine ring, and its intended pharmacological use. If a product is determined to be a drug, possesses an unfused pyridine ring, and does not fit into the psychotherapeutic agent category, it will be classified under this residual "Other" designation.

Stay Updated

Join our newsletter to get all updates of the harmonized Tariff Schedule.